Share on StockTwits

Shares of Pfizer (NYSE:PFE) were the target of unusually large options trading activity on Wednesday. Traders bought 30,762 call options on the stock, AnalystRatings.Net reports. This represents an increase of 131% compared to the typical daily volume of 13,303 call options.

A number of analysts have recently weighed in on PFE shares. Analysts at Deutsche Bank initiated coverage on shares of Pfizer in a research note on Wednesday, August 27th. They set a “buy” rating and a $34.00 price target on the stock. They noted that the move was a valuation call. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Pfizer in a research note on Friday, August 22nd. They now have a $30.00 price target on the stock. Finally, analysts at Credit Suisse cut their price target on shares of Pfizer from $35.00 to $34.00 in a research note on Thursday, August 14th. Seven investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $33.54.

Shares of Pfizer (NYSE:PFE) traded up 0.48% on Wednesday, hitting $29.40. 21,118,070 shares of the company’s stock traded hands. Pfizer has a 52-week low of $27.87 and a 52-week high of $32.96. The stock has a 50-day moving average of $29.28 and a 200-day moving average of $30.28. The company has a market cap of $186.4 billion and a price-to-earnings ratio of 18.38.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, July 29th. The company reported $0.58 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.57 by $0.01. The company had revenue of $12.80 billion for the quarter, compared to the consensus estimate of $12.49 billion. During the same quarter in the prior year, the company posted $0.56 earnings per share. The company’s quarterly revenue was down 1.5% on a year-over-year basis. On average, analysts predict that Pfizer will post $2.25 earnings per share for the current fiscal year.

Pfizer Inc (NYSE:PFE) is a research-based, global biopharmaceutical company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.